Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Demonstrate the Relative Bioavailability of Fixed Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects

NCT02688387 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02688387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02688387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Demonstrate the Relative Bioavailability of Fixed Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
March 18, 2016
Completion date
August 4, 2017
Enrollment
112 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, pulmonary